Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

By Y. Liaw, N. Leung, Ting Chang, R. Guan, D. Tai, K. Ng, R. Chien, J. Dent, Lise Roman, S. Edmundson and 1 more. Gastroenterology, 2000

730 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/c178c872ca138afe2ffd915bcca04bc03077d2c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Boehme
2. M. Atkins
3. C. Hunt
4. N. Brown

Citations in the corpus

• Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. (2003, methodology): “Among the 93 patients treated with lamivudine (100 mg) for 2 years, YMDD variants were detectable in 31 (42%) of the 74 with data available for analysis at week 104 [23].”